Key Stats for ResMed Stock
- Price Change: -1.3%
- Current Price: $251
- Advanced Model Price Target: $382
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Shares of ResMed Inc. (RMD) slipped 1.3% to close at $251 on Tuesday as investors digested a strong second-quarter earnings report.
The company reported Q2 2026 headline revenue growth of 11.0%, driven by high single-digit device growth and double-digit growth in masks and accessories.
Moreover, management recently made waves by ramping up doctor outreach to tap into the GLP-1 surge, identifying these patients as highly motivated therapy users.
Furthermore, analysts at Goldman Sachs recently maintained a Neutral rating, focusing on the lumpiness of the ex-U.S. device market, which saw 5.0% constant currency growth.
Meanwhile, Jefferies analysts questioned the impact of potential competitive reentry from peers like Philips (NYSE:PHG) in the U.S. market.
Additionally, sector competitors such as Fisher & Paykel Healthcare (ASX:FPH) also continue to navigate global supply chain efficiencies as demand for sleep health solutions accelerates.
Not to mention, the firm remains an innovation machine, recently launching the F30i Comfort fabric masks to change the basis of competition in the mask market.
See analysts’ growth forecasts and price targets for ResMed stock (It’s free!) >>>
Is ResMed Undervalued Today?
On the latest conference call, CEO Mick Farrell emphasized that the company is effectively a sleep health and breathing health “excellence machine.”
He stated: “We delivered another strong quarter with 11.0% headline revenue growth… achieving GAAP EPS growth of 16.0%, strong double-digit bottom line growth.”
Moreover, regarding the long-term potential of patients using GLP-1 weight loss medications, he provided encouraging real-world evidence.
Furthermore, he noted: “Ultimately, what we’re finding is patients on a GLP-1 get on CPAP more and stay on CPAP therapy longer.”
Additionally, management believes they are only in “mile 1 of the marathon” despite already serving people in over 140 countries worldwide.
Read the full RMD Transcript on TIKR to see the GLP-1 tailwind data >>>
According to TIKR’s Advanced Valuation Model, the stock is positioned for significant capital appreciation as the market realizes the durability of the current growth cycle.
- Advanced Model Price Target: $382
- Current Price: $251
- Potential Upside: +51.9%
The investment case for ResMed (RMD) rests on its dominant global market share and the transition toward an AI-enabled digital health ecosystem.
Besides, if ResMed (RMD) continues to educate primary care physicians and successfully rolls out its AI-enabled Comfort Match technology, the gap to $382 could close rapidly.
Conclusion: The sleep health giant is engineered for a 2026 breakout. With a 51.9% upside potential and a model pointing to $382, ResMed stock offers a resilient mix of double-digit earnings growth and high-tech operational dominance through 2026.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
How Much Upside Does ResMed Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
